AGEPHA Pharma
- Company typePrivate
- Founded1947
- HeadquartersSenec
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
AGEPHA Pharma firmographics
Firmographics- Name
- AGEPHA Pharma
- Website
- https://agephapharma.com
- Company type
- Private
- Founded year
- 1947
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Where AGEPHA Pharma is headquartered
LocationHeadquarters
- HQ city
- Senec
Markets served
AGEPHA Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Marketing or Sales, Personnel, Operations, Technology or R&D, Supply Chain
Revenue model
- Pharmaceutical Drug Sales: AGEPHA Pharma generates revenue through the sale of proprietary pharmaceutical drugs. The company received FDA approval for Lodoco (colchicine-based) for cardiovascular disease in 2023, representing a repurposed drug with premium pricing strategy.
Go-to-market motion1 record
Distribution channels2 records
Marketing channels3 records
AGEPHA Pharma product offering
Product offeringCore offering
AGEPHA Pharma is a specialty pharmaceutical company that develops and commercializes prescription drugs, with a primary focus on its FDA-approved cardiovascular product Lodoco (colchicine 0.5 mg), the first anti-inflammatory medication approved for reducing the risk of heart attack, stroke, coronary revascularization, and cardiovascular death in patients with established atherosclerotic disease or multiple risk factors. The company also operates in adjacent areas including dietary supplements, ophthalmology, dermatology, and vitamins and minerals.
Product overview
AGEPHA Pharma is a specialty pharmaceutical company with a focused portfolio centered on its FDA-approved product Lodoco, a colchicine-based cardiovascular treatment. The company operates in the repurposed drug space, bringing established molecules to new therapeutic indications through regulatory approval.
Differentiator
Problem solved
Functional benefit
Products and services
- Lodoco (colchicine 0.5 mg tablet)
Companies that use AGEPHA Pharma
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles1 record
AGEPHA Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
AGEPHA Pharma partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Close-Up IntlcoreClose-Up Intl provides AI-powered CRM technology deployed across AGEPHA Pharma's U.S. sales force. The platform offers real-time healthcare professional insights, digital omnichannel engagement capabilities, Direct-to-Practitioner sampling functionality, and performance intelligence designed to enhance field productivity and sales force effectiveness. The collaboration is intended to help AGEPHA Pharma increase productivity and more effectively manage its business in the competitive U.S. pharmaceutical market.
Scale indicators2 records
Recent moves4 records
Expansion highlights4 records
AGEPHA Pharma competitors and assessment
Company assessmentBroad incumbents
- Pfizer: Pfizer is a broad incumbent with established cardiovascular and cardiometabolic franchises and dominant relationships with U.S. cardiologists. It is comparable as a competitive backdrop for Lodoco's U.S. launch.
- AstraZeneca: AstraZeneca has a major cardiovascular franchise (e.g., Brilinta, Farxiga) and is a dominant incumbent in cardiovascular risk reduction. It is comparable as a competitor prescriber-side for Lodoco within cardiology.
- Novartis: Novartis operates a large cardiovascular portfolio (e.g., Entresto, Leqvio). It is comparable to AGEPHA as a broad incumbent shaping the competitive landscape where Lodoco is being commercialized.
Direct peers
- ANI Pharmaceuticals: ANI is a U.S. specialty pharma company that markets branded and generic prescription products, including cardiovascular and specialty care medicines. It is comparable to AGEPHA as a smaller specialty pharma commercializing niche prescription products through targeted physician channels.
- Takeda Pharmaceutical: Takeda markets Colcrys (colchicine), the established colchicine brand in the U.S. It is the most direct competitor to AGEPHA's Lodoco since both products use colchicine as the active ingredient, though for different indications.
- Hikma Pharmaceuticals: Hikma is a specialty pharmaceutical company with branded and generic product portfolios including cardiovascular therapies. It is comparable to AGEPHA in business model — a specialty pharma commercializing differentiated prescription products to physicians.
Emerging players
- BioXcel Therapeutics: BioXcel is a clinical-stage company working on repurposed and reformulated therapies in immunology and neuroscience. It is comparable to AGEPHA in applying a repurposing model to bring differentiated therapeutics to market.
- TherapeuticsMD: TherapeuticsMD is a specialty pharmaceutical company commercializing branded prescription products in focused therapeutic areas. It is comparable to AGEPHA as a small-cap specialty pharma targeting specific prescriber segments with differentiated branded products.
- Apnimed: Apnimed is a clinical-stage pharma developing repurposed drugs for sleep apnea and related indications. It is comparable to AGEPHA as a smaller company pursuing a repurposed-drug strategy into new therapeutic indications.
Regional players
- Zentiva: Zentiva is a European specialty and generic pharmaceutical company based in the Czech Republic/Slovakia region. It is comparable to AGEPHA as a Central European specialty pharma with overlapping therapeutic areas and similar geographic roots.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
AGEPHA Pharma social profiles
Digital presenceAGEPHA Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
AGEPHA Pharma leadership team
Management profileNumber of profiles
AGEPHA Pharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
AGEPHA Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about AGEPHA Pharma
What does AGEPHA Pharma do?
AGEPHA Pharma is a specialty pharmaceutical company that develops and commercializes prescription drugs, with a primary focus on its FDA-approved cardiovascular product Lodoco (colchicine 0.5 mg), the first anti-inflammatory medication approved for reducing the risk of heart attack, stroke, coronary revascularization, and cardiovascular death in patients with established atherosclerotic disease or multiple risk factors. The company also operates in adjacent areas including dietary supplements, ophthalmology, dermatology, and vitamins and minerals.
When was AGEPHA Pharma founded?
AGEPHA Pharma was founded in 1947. It employs 51 to 100 people.
Where is AGEPHA Pharma based?
AGEPHA Pharma is headquartered in Senec.
How does AGEPHA Pharma make money?
One revenue line is on record: pharmaceutical Drug Sales.
Who are AGEPHA Pharma's main competitors?
Broad incumbents on record are Pfizer, AstraZeneca and Novartis. Direct peers are ANI Pharmaceuticals, Takeda Pharmaceutical and Hikma Pharmaceuticals. Emerging players are BioXcel Therapeutics, TherapeuticsMD and Apnimed. Zentiva is listed as a regional player.
Does AGEPHA Pharma have an API?
No public API is recorded for AGEPHA Pharma.